Search results
Results from the WOW.Com Content Network
Federal health officials have approved the first pill specifically intended to treat severe depression after childbirth, a condition that affects thousands of new mothers in the U.S. each year.
The FDA approval of zuranolone marks “a very important step forward” for the field of maternal mental health, Dr. Samantha Meltzer-Brody, director of the Center for Women’s Mood Disorders at ...
Brexanolone was approved for medical use in the United States in 2019. [ 11 ] [ 15 ] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication . [ 16 ] The long administration time, as well as the cost for a one-time treatment, have raised concerns about accessibility for many women.
Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. [5] [6] It is taken by mouth.[5]The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection.
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
The Food and Drug Administration (FDA) has approved the first pill to treat postpartum depression (PPD), the agency announced Friday. Zurzuvae is the market’s first pill medication for the ...
Use during pregnancy and breastfeeding is not generally recommended. [7] It is in the serotonin modulator class of medications and is believed to work both as an SSRI and activator of the 5-HT 1A receptor. [1] Vilazodone was approved for medical use in the United States in 2011 [1] and in Canada in 2018. [8]
For premium support please call: 800-290-4726 more ways to reach us